drugset / Trial / NCT02039531

Effect Of Plasma Rich In Growth Factors In Knee Osteoarthritis

NCT02039531

RandomizedParallel-groupSingle-blindTreatment

Summary

HYPOTHESIS: The application of plasma rich in growth factors (PRGF) will improve the quality of life and functional capacity of patients diagnosed with knee osteoarthritis, providing better functional results than conventional treatment with viscosupplementation. OPERATING ASSUMPTIONS Following the initial administration of three doses of PRGF interspersed every 15 days, applied via intraarticular, patients will present an improvement in functional test (WOMAC and Lequesne scales) of 15% or more after 6 and 12 months compared to the control group with patients treated with hyaluronic acid.

Timeline

Start
2011-08
Primary completion
2013-02
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hyaluronic Acid Other / unclassified Other
Subject Plasma rich in growth factors Other / unclassified Other

Indications